LONZA N revenue for the last year amounted to 6.72 B CHF, the most of which — 3.72 B CHF — came from its highest performing source at the moment, Biologics, the year earlier bringing 3.27 B CHF. The greatest contribution to the revenue figure was made by United States — last year it brought LONZA N 2.14 B CHF, and the year before that — 2.42 B CHF.